Brief: Cosmo: successful outcome of phase III clinical trial for Rifamycin SV MMX
06/06/2016 06:01
June 6 (Reuters) - Cosmo Pharmaceuticals SA COPN.S :
* Cosmo announces successful outcome of phase III clinical trial for Rifamycin SV MMX
Source text for Eikon: ID:nTEN9s84ra
Further company coverage: COPN.S
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Cosmo Advanced Materials & Technology
See all newsQ2 2026 Operating Profit Up 779.9% YoY To Won 4.65 Billion
Brief: Cosmo Advanced Materials & Technology Q1 Operating Profit 874 Million Won, Down 16.3% From Year Earlier
Brief: Cosmo Advanced Materials & Technology Q3 Operating Profit 135 Million Won, Down 98% From Year Earlier
Brief: Cosmo Advanced Materials & Technology Q2 Operating Profit 529 Million Won, Down 92.4% From Year Earlier
Brief: Cosmo Advanced Materials & Technology Q1 Operating Profit 1 Billion Won, Down 80.3% From Year Earlier